Clinical trials: Lipoprotein Disorder
Vitamin K Deficiency
Incorporation of Vitamin K Into Uremic Lipoproteins
Chronic kidney disease (CKD) patients have an increased cardiovascular risk with corresponding cardiovascular calcifications. CKD patients exhibit a functional vitamin K deficiency.
- Trial name
- NCT05360342
- Testing
- Vitamin K supplement
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Coronary Disease
A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)
This purpose of this study is to determine if the administration of ezetimibe and simvastatin together is more effective than simvastatin alone in lowering LDL-C levels to a goal of <100 mg/dL in patients at risk for Heart…
- Trial name
- NCT00551447
- Testing
- MK0653, ezetimibe / Duration of Treatment: 27 Weeks, MK0733, simvastatin / Duration of Treatment: 27 Weeks, Comparator: simvastatin / Duration of Treatment: 27 Weeks
- Volunteers
- 616 people
- Sponsor
- Organon and Co
Atherosclerosis, Coronary Disease
Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis
To evaluate whether specific lipoprotein(a) apheresis on the top of optimal medical therapy could affect atherosclerotic disease burden in coronary and carotid arteries of coronary heart disease patients with elevated Lp(a)…
- Conditions
- Atherosclerosis, Coronary Disease, Carotid Artery Diseases
- Trial name
- LaRCA (NCT02133807)
- Testing
- Specific Lp(a) apheresis
- Where
- Russia
- Volunteers
- 32 people
- Sponsor
- Russian Cardiology Research and Production Center
Cardiovascular Disease
Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
Background: Cardiovascular disease (CVD) is a leading cause of death in developed countries. Although statin-type drugs are currently the most effective therapeutic agents for reducing CVD risk.
- Trial name
- NCT01131299
- Testing
- Alpha cyclodextrin
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Polycystic Ovary Syndrome
Effect of Exercise on Cardiometabolic Profile in Women With Polycystic Ovary Syndrome
Polycystic Ovary Syndrome (PCOS) is a complex hormonal and metabolic disorder that has been shown to affect women's fertility. It can also share many symptoms with pre-diabetes, and women with PCOS often have an increased risk…
- Trial name
- NCT03678714
- Testing
- Exercise Intervention, Lifestyle Physical Activity
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Sheffield Hallam University
Exogenous Obesity, Dietary Modification
Thermic & Lipemic Properties of Dietary Carbohydrates
The purpose of this study is to determine if consumption of meals containing carbohydrates with different glycemic index (a high glycemic index meal and a low glycemic index meal)have different effects on energy expenditure, type…
- Trial name
- FL33 (NCT01354574)
- Testing
- High Glycemic Index meals, Low Glycemic Index meals
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
Atherosclerotic Cardiovascular Disease
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
This is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory…
- Trial name
- AZD0780-ABPM (NCT06692764)
- Testing
- AZD0780
- Where
- 26 sites in United States
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Cardiovascular Disease and Lipoprotein(a)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
- Trial name
- NCT07517263
- Testing
- Pelacarsen (TQJ230)
- Where
- 646 sites in United States, Argentina and 38 more
- Volunteers
- 5,700 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation, Chronic Kidney Disease
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
This study is designed to investigate the role of lipids/lipoproteins as a potential cause for the harmful changes seen in fibrin clot properties with renal dysfunction and atrial fibrillation
- Trial name
- RALiC (NCT04043026)
- Testing
- Statin
- Where
- 2 sites in United Kingdom
- Volunteers
- 56 people
- Sponsor
- University of Liverpool
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI
- Trial name
- C-STAR (NCT05661552)
- Testing
- Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Yonsei University